ATP synthase membrane subunit c locus 2Genealiases: ATP5A · ATP5G2
Q-omics provides the consensus-scored ATP5MC2 profile across patient tissues and cancer cell-line models. ATP5MC2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ATP5MC2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ATP5MC2 RNA expression shows 18,653 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where ATP5MC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MC2 survival associations across molecular data types. ATP5MC2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MC2 RNA expression–survival associations across cancer types. High ATP5MC2 expression shows unfavorable associations in ACC, LIHC, KICH, KIRC and LUAD, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ATP5MC2 RNA expression.
This table summarizes ATP5MC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ATP5MC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MC2 shows higher tumor expression in KIRC, LIHC, KIRP, BRCA, CHOL and LUSC. The KIRC box plot shows higher ATP5MC2 RNA expression in tumor versus normal tissue (log2 FC = +0.758, t-test p < 0.001).
This table shows molecular features associated with ATP5MC2 in patient tissues and cancer cell lines. In patient samples, ATP5MC2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP5MC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
